Amendment #10, as changed to H3872

Authorization of Opioid Use Disorder Medication Administration

Mr. Cahill of Lynn moves to amend the bill, as amended, by striking out the amendment in its entirety and inserting in place thereof the following:-

Mr. Cahill of Lynn moves to amend the bill by inserting, after section 27A, the following section:-

SECTION 27B. Notwithstanding any other general or special law or regulation to the contrary, a pharmacist or pharmacy intern licensed by the board of registration in pharmacy and in good standing with the board may administer methadone and buprenorphine as medication for the treatment of opioid use disorder in federally certified and Bureau of Substance Addiction Services licensed opioid treatment programs and certified acute treatment services pursuant to a qualified practitioner’s order; provided, however, that administration of methadone and buprenorphine as medication for the treatment of opioid use disorder drugs shall be conducted in accordance with federal Substance Abuse and Mental Health Services Administration regulations, 42 CFR Part 8 and the policies and procedures established in accordance with 105 CMR 164.000 et seq; and provided further, that prior to administering drugs under this section, a pharmacist or pharmacy intern shall receive training in federal confidentiality regulation.

And further moves to amend the bill by inserting, after section 28, the following section:-

SECTION 28A. Section 27B are hereby repealed.

And further moves to amend the bill by inserting, after section 31, the following section:-

SECTION 32. Section 28A shall take effect on April 1, 2022 or 10 days following the revocation of the United States declaration of a national emergency concerning the novel coronavirus diseases, whichever is earlier.